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Abstract
Objectives: Hepatic steatosis is associated with an increased risk of developing serious liver disease and other clinical
sequelae of the metabolic syndrome. However, visual estimates of steatosis from histological sections of biopsy samples are
subjective and reliant on an invasive procedure with associated risks. The aim of this study was to test the ability of a rapid,
routinely available, magnetic resonance imaging (MRI) method to diagnose clinically relevant grades of hepatic steatosis in
a cohort of patients with diverse liver diseases.
Materials and Methods: Fifty-nine patients with a range of liver diseases underwent liver biopsy and MRI. Hepatic steatosis
was quantified firstly using an opposed-phase, in-phase gradient echo, single breath-hold MRI methodology and secondly,
using liver biopsy with visual estimation by a histopathologist and by computer-assisted morphometric image analysis. The
area under the receiver operating characteristic (ROC) curve was used to assess the diagnostic performance of the MRI
method against the biopsy observations.
Results: The MRI approach had high sensitivity and specificity at all hepatic steatosis thresholds. Areas under ROC curves
were 0.962, 0.993, and 0.972 at thresholds of 5%, 33%, and 66% liver fat, respectively. MRI measurements were strongly
associated with visual (r2 = 0.83) and computer-assisted morphometric (r2 = 0.84) estimates of hepatic steatosis from
histological specimens.
Conclusions: This MRI approach, using a conventional, rapid, gradient echo method, has high sensitivity and specificity for
diagnosing liver fat at all grades of steatosis in a cohort with a range of liver diseases.
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Introduction
Fatty liver disease is associated with an increased risk of
carcinoma, cardiovascular death, cirrhosis, reduced effectiveness
of antiviral treatments, and is implicated in the development of
diabetes [1]. A visual estimate of the fat content in a liver biopsy
specimen by a histopathologist is considered the gold standard for
clinically assessing liver fat. Liver fat levels are generally estimated
by the percentage of hepatocytes containing intracellular fat
vacuoles graded categorically on a scale from 0 to 3 [2] or on a
continuous scale from 0 to 100%. Visual estimates of liver fat in
biopsy samples are subjective, have poor reproducibility [3], are
potentially unrepresentative of the whole liver and require an
invasive procedure with associated risks to obtain the sample [4].
Some patients with fatty liver disease are biopsied as part of their
routine clinical assessment to determine the severity of fibrosis or
inflammation. However, with obesity now common in developed
countries there is increased interest in non-invasive methods of
quantifying liver fat content for research purposes, diagnosis, and
monitoring intervention programs.
Magnetic resonance imaging (MRI) and spectroscopy (MRS)
have been used for decades to qualitatively and quantitatively
assess liver fat [5,6]. Spectroscopy is currently considered the most
accurate quantitative MR method for measuring liver fat, but
imaging approaches based on the Dixon method offer the
advantage of assessing larger regions of the liver in a comparatively
short time and with simpler image processing. Furthermore, use of
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MRS is largely limited to research settings due to the technical
expertise and cost required to routinely deliver it.
While several reports have compared histological liver fat
estimates with quantitative MRI approaches [7–25], there are
fewer studies [7,9,15,22,23,26,27] which have assessed the
diagnostic performance of MRI using a pathologist’s visual
estimate of fat content as the reference standard to identify the
clinically relevant thresholds as defined by the Nonalcoholic
Steatosis Clinical Research Network (NASH CRN) [2,28]. The
largest of these diagnostic studies [15] investigated a cohort of
potential living donors without any documented liver disease.
Some studies have also supplemented the histopathologist’s visual
estimate of fat with computer assisted image processing techniques
to objectively measure the area and hence volume fraction
occupied by vesicular fat in the biopsy histological section. These
image-processing approaches generally use either stereology
counting [20,21] or image segmentation [16] with shape analysis
[18,19,29] to quantify the area of fat in a biopsy sample. Only two
studies [18,29] have compared a quantitative MRI method to fat
measurements based on a histopathologist’s visual estimate and
those based on morphometric image analysis of the biopsy
histological section.
The general approach for measuring liver fat using MRI is to
reduce or correct for confounding factors so that there is, as close
as possible, a linear, one-to-one relationship between the measured
MRI signal and the volume fraction of liver fat. While potentially
improving the direct relationship between the MRI signal and
liver fat, the acquisition adjustments to minimise confounding
factors lead to poor signal to noise in the acquired images,
reducing the generic diagnostic quality and potentially the
diagnostic sensitivity. Rather than attempt to obtain a measured
signal that accurately represented the proton density ratio of fat to
water, we took a calibration-based approach that purposefully
distorted the measured signal away from the fat-water proton
density ratio in order to increase the sensitivity of the measurement
to the presence of fat and maintain diagnostic image quality.
Hence, the primary aim of this study was to test the ability of this
approach, which comprised a triple gradient echo, single breath-
hold MRI method, to diagnose clinically relevant grades of hepatic
steatosis in a diverse cohort using a histopathologist’s visual
estimate of fat content as the reference standard according to the
NASH CRN thresholds [2,28]. A secondary aim was to measure
the diagnostic performance of MRI to grade liver fat when a
reference standard based on quantitative computer assisted
morphometric image analysis of histological sections was used
instead of a histopathologist’s visual assessment.
Materials and Methods
Ethics Statement
Written informed consent was obtained from each subject and
the study protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki as reflected in approval by the Fremantle
Hospital Human Research Ethics Committee and the Sir Charles
Gairdner Hospital Human Research Ethics Committee.
Subjects
Ten healthy controls and 65 patients were enrolled in the study.
The patients were recruited from the hepatology outpatient clinics
at Fremantle and Sir Charles Gairdner Hospitals, Western
Australia. The patient inclusion criteria were: age between 18
and 75 years and written informed consent. Control subjects were
not biopsied and required a body mass index (BMI) less than 25
and no history of liver disease. The control subjects were included
to provide a baseline of normal liver fat levels as measured by this
MRI technique. Exclusion criteria were: contraindications for
MRI, pregnancy or lactation. One patient was also excluded after
their history indicated fluctuations in weight and alcohol
consumption during the study period. An additional five cases
were excluded for incorrect MRI acquisition or unavailability of
images for morphometric analysis leaving 59 patients that entered
the study (Table S1 in File S1).
Liver Histology and Quantification of Liver Fat
The patients underwent percutaneous liver biopsy with
ultrasound guidance as part of their routine clinical management.
Each liver biopsy specimen was reviewed by an experienced
hepatopathologist (PB), blinded to the patient’s identity and MRI
data, who visually estimated the percentage of hepatocytes
containing fat on a continuous scale between 0% and 100%
(HIS-VIS). The METAVIR scoring system was used to stage the
amount of fibrosis.
Computer Assisted Morphometric Image Analysis of Liver
Fat Area
The fraction of vesicular fat vacuoles in Masson’s trichrome
stained histological sections was assessed by computer assisted
morphometric image analysis. Histological sections of the biopsies
were scanned in colour using an Aperio Scanscope XT (Aperio
Technologies, Inc., California, USA) automated slide scanner and
ImageScope software. Using ImageJ 1.42 (NIH, USA) software,
the fat vacuoles were automatically identified and areas measured
in a multi-stage process using thresholding, size, and circularity
criteria. Fat vacuoles, holes, tears or vessels in the biopsy section
appear as high intensity (white) areas (Figure 1A). These high
intensity regions were automatically segmented by applying a
threshold intensity of 220 (out of 256) on the green image band,
which on inspection provided the best contrast between fat
vacuoles and liver parenchyma. The threshold image was
converted into a binary image such that the fat vacuoles and
any other high intensity regions were given a value of 255 and
non-fat tissue a value of 0 (Figure 1B). The fat vacuoles were then
automatically identified and delineated using the Analyze Particles
tool in ImageJ with a circularity index between 0.5 and 1 and a
size threshold between 100 and 10000 pixels (equivalent to
diameters from 5.6 to 56 mm). The circularity index ranges from 0
(infinitely elongated polygon) to 1 (perfect circle) and is defined as
(4p 6Area)/Perimeter2.
The criteria for thresholding intensity, size, and circularity were
established by inspection of the results of different thresholds, sizes
and circularities on the effective simultaneous exclusion of large
vessels, ducts or other large areas of high intensity and inclusion of
fat vacuoles. The analysis produced the size and circularity of each
individual fat vacuole and the total area of all the fat vacuoles
within the threshold ranges. To compute the total area of the
biopsy sample, the binary image was reversed and the Fill Holes
tool used to produce a biopsy image without holes. The total area
of the biopsy sample was measured and the areal fat fraction (HIS-
MORPH) computed from the ratio of fat area to total biopsy tissue
area.
MRI
Data acquisition. All MRI measurements were made on
Siemens 1.5 T Avanto scanners (Siemens Medical Systems,
Erlangen, Germany) at Fremantle Hospital, St John of God
Murdoch Hospital, and Hollywood Private Hospital, Western
Australia. The median time between biopsy and MRI was 57 days.
Measuring Hepatic Steatosis with MRI
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Phased-array torso coils were centred over the liver of the subjects.
MRI acquisition comprised an opposed-phase, in-phase, opposed-
phase gradient echo sequence (TEs 2.38, 4.76, 7.14 ms, TR
88 ms, 1 excitation, flip angle 70 degrees, bandwidth 500 Hz).
Data from three axial slices, positioned through the widest part of
the liver, were acquired in a single breath-hold. The slice thickness
was 4 mm and the matrix was 2566256 with a field of view
3006300 mm. Liver iron concentrations (LIC) were measured
using a validated non-invasive MRI method (FerriScanH) [30–32].
Image processing. A single analyst (MJH), blinded to the
identity and medical histories of the subjects, reviewed and
processed all images using ImageJ 1.42 (NIH, USA). On each of
the three slices a circular region of interest (ROI) about 580 mm2
was delineated within the right lobe of the liver, avoiding large
intrahepatic vessels and any obvious motion-affected regions
(Figure 2). The average image intensities within the ROIs, for all
three echoes and slices, were used to calculate a parameter, a,
(Eqn. 1). The final value of a reported was the average for the
three slices. The parameter a can take any value between 0 and 1
and is related to the liver fat concentration, but is also dependent
on the MRI pulse sequence parameters.
The parameter a in the liver ROI was calculated for each slice
using the following equation:
a~ IP{OP1 exp TE1{TE2ð Þ=T2ð Þ½ f g=2IP ð1Þ
where IP is image intensity in the ROI of the first in-phase image,
OP1 is image intensity in the ROI of the first opposed-phase
image, TE1 is the first opposed-phase echo time, and TE2 is the
in-phase echo time [33]. A T2
* estimate for correcting the T2
*
signal decay of the OP1 echo was derived from the two OP images
using the equation:
T2 ~ TE3{TE1ð Þ= ln OP1=OP2ð Þ½  ð2Þ
where OP1 and OP2 are the signal intensities in the ROI of the
first and second opposed phase images, TE1 is the first opposed-
phase echo time, and TE3 is the second opposed-phase echo time.
Analysis. The relationship between a and the volume
fraction of fat in the liver is not expected to be linear owing to
both the difference in proton density between fat and the
surrounding tissue and the difference in T1 (the MRI related
parameter known as the longitudinal relaxation time constant)
between fat and the surrounding tissue. The relationship between
a and volume fraction (f) of fat in the liver is expected to be of the
form.
a~kf = 1zkf {fð Þ ð3Þ
where k is a constant [33]. Since the fat vacuoles are approxi-
mately spherical and the histological sections are thin compared to
the size of the fat vacuoles, the area fraction of the histological
section accounted for by fat vacuoles (HIS-MORPH) will be equal
to the volume fraction of fat in the liver tissue.
Statistical Analysis
Descriptive clinical and demographic characteristics were
compared using Chi-squared analysis (for categorical data), the
Figure 1. Example of histology images and morphometric image analysis. A) Histologic image of a liver (Masson trichrome,620 objective),
B) Binary image of same image after application of threshold, C) Mask showing fat vacuoles after application of size and structural criteria, D)
Examples of binary histology images with measured fat percentage areas. These images have been thresholded as in 1B, but not masked (as in 1C), so
as to keep the additional white spaces that are not represented in the areal fat estimate, but are visible in a histology image. Each square is 500
microns across.
doi:10.1371/journal.pone.0059287.g001
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Student’s t test (for continuous parametric data), or the Mann-
Whitney test (for non-parametric data). Data were tested for
normality using the Komolgorov-Smirnov test. Non-Gaussian
distributions were summarised by their median value and range.
For non-Gaussian distributions the 95% prediction interval was
calculated on the log-transformed data. Relationships between
continuous parameters were assessed using the coefficient of
determination (r2). The performance of the MRI technique for
predicting the histologically measured fat grades was assessed
using receiver operating characteristic (ROC) curve analysis. The
area under the ROC curve (AUC) was used to assess the
diagnostic performance of the MRI method against the biopsy
observations. The thresholds of a were identified by the cut-off
that produced the highest combined sum of sensitivity and
specificity for distinguishing histological fat scores above and
below the standard thresholds. Two ROC curve analyses were
performed. The first analysis used the NASH CRN histological
scoring system cut-off values of $5%, .33%, and .66% liver fat
[2], as determined by the visual estimation of the hepatopathol-
ogist (PB), to define the diagnostic groups above and below the
three cut-offs. A second ROC curve analysis used cut-offs in HIS-
MORPH fractions of $0.014, .0.043, and .0.077. These
morphometric cut-offs were derived from the regression line of
HIS-MORPH against HIS-VIS using the visual histopathologist
cut-offs of 5%, 33% and 66% as input into the regression
equation. The methods of Bland and Altman [34] were used to
assess the 95% limits of agreement between MRI and biopsy
(HIST-MORPH) fat estimates. A p value less than 0.05 was
considered statistically significant.
Results
Demographic and Clinical Data
The control subjects were younger and had lower BMIs than
the patients (Table 1). BMI values were normally distributed.
Thirty-two patients had no/mild fibrosis (METAVIR 0 or 1) and
27 patients had moderate/severe fibrosis (METAVIR 2, 3 or 4).
Five patients had liver iron concentration levels above the normal
maximum level of 1.8 mg[Fe]/g dry tissue. The median liver fat
level of the 59 patients was 5% (range 0 to 98%) from HIS-VIS
and 0.029 (range 0.002 to 0.216) from HIS-MORPH. The median
value of a for the control subjects (0.024, range 0.013 to 0.105) was
significantly lower compared with the patients (0.072, range 0.01
to 0.41, p = 0.012). The 95% prediction interval of a for the
control subjects was 0.008 to 0.094. This prediction interval can be
viewed as an estimate of the reference range of MRI a values for
healthy subjects without liver problems. Interestingly, one of the
ten control subjects without any recognised liver condition was
outside this reference range.
Performance of MRI for Predicting Histological Fat Levels
The ROC curve analyses are summarised in Tables 2 and 3.
The analyses showed that the MRI a values had high AUCs,
sensitivities and specificities at all three liver fat thresholds (Table 2,
3). Based on the ROC curve analysis, the clinically relevant NASH
CRN steatosis grade boundaries of 5%, 33% and 66% correspond
to MRI a values of 0.067, 0.135, and 0.171, respectively (Table 2).
There were no significant differences between the AUC’s from
morphometric image analysis compared with the pathologist’s
visual estimate (Table 2, 3).
Relationship between MRI and Histology
Figure 3 shows a fit of Equation 3 to the a versus HIS-MORPH
data. The coefficient of determination, r2, for this fit was 0.84.
Linear regression analysis showed that there were significant
coefficients of determination between the pathologist’s visual
estimates of fat (HIST-VIS) and a from the MRI measurement
(r2 = 0.83, Fig. 4) and between the pathologist’s visual estimates of
fat (HIST-VIS) and the morphometric fat fraction HIS-MORPH
(r2 = 0.72).
Limits of Agreement between Liver Fat Measurements
The MRI alpha results were transformed to equivalent HIST-
MORPH values using Eqn. [3] and these values (MRI HIST-
MORPH fat fraction) are plotted against the HIST-MORPH
measurements (Figure 5a). A plot of the difference against the
mean of the two measurements indicated that there was an
increase in the variance of the difference between the measure-
ments as the magnitude increased. Hence, the measurements were
not amenable to Bland and Altman [34] analysis without
transformation. The natural logarithms of each measurement
were therefore calculated and the difference between the natural
logarithms of the two fat measurements plotted against the mean
of the two natural logarithms of the fat measurements (Figure 5b).
Figure 2. Axial magnetic resonance images of a patient with a typical ROI (solid grey circle) used for fat analysis. A) 2.38 ms (opposed
phase), B) 4.76 ms (in phase), C) 7.14 ms (opposed phase).
doi:10.1371/journal.pone.0059287.g002
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There was no significant correlation between the differences and
the mean of the liver fat logarithms (Spearman’s rank order
correlation coefficient rho = 0.1051, p = 0.4283). The mean
difference between the measurements (20.103, standard devia-
tion = 0.495) was not significantly different from 0 (p = 0.1167).
Furthermore, the mean differences between measurements for
each of the three different scanners used in the study were not
significantly different from zero (p = 0.65, 0.12, and 0.32). The
upper and lower 95% limits of agreement between the two
logarithms of fat measurements were found to be 21.073 (95% CI
21.296 to 20.85) and 0.868 (95% CI 0.645–1.091), respectively
(Figure 5b). These limits of agreement correspond to 95% of pairs
of liver fat measurements being expected to have ratios (fat
fraction measured by morphometry to fat fraction measured by
MRI) between 0.342 (95% CI 0.274–0.427) and 2.382 (95% CI
1.907–2.976).
Discussion
In this cohort of patients with heterogenous liver disease, a
simple, rapid, quantitative MRI measurement based on in-phase
and opposed-phase imaging can provide clinically relevant
diagnostic information on liver fat levels. The MRI technique
demonstrated high levels of sensitivity and specificity at all
clinically relevant thresholds of liver fat ($5%, .33%, .66%)
[2], using the gold standard of liver fat estimated by a pathologist
from a biopsy sample. At these three cut-offs we achieved areas
under ROC curves of 0.962, 0.993, and 0.972, respectively. Our
results compare favourably to the small number of studies that
have used a pathologist’s visual estimate of fat content as the
reference standard to define thresholds and assess the diagnostic
performance of comparable MRI approaches [7,9,15,22,23,26,27]
(see Table S2 in File S1). The MRI technique presented here has
higher areas under ROC curves for all liver fat thresholds
described in the literature (Table S2 in File S1), except for two
studies [7,15] investigating liver fat in non-diseased cohorts
(potential living donor candidates). At 5% or more fat, our AUC
was marginally lower (0.962 versus 0.987) than the result from Joe
et al. [7] and, at 30% or more fat, Lee et al. [15] reported an
AUC of 0.995 compared to our result of 0.992. For identifying
subjects with histological fat $5%, McPherson et al. [22]
calculated separate areas under ROC curves for subjects with
METAVIR fibrosis stage 1 and below (AUC = 0.97) and subjects
with METAVIR fibrosis stage 2 and above (AUC = 0.87). When
analysed on a similar basis, our data gave AUCs of 0.95 and 0.99
respectively.
Table 1. Clinical data of the study cohort.
Characteristics Controls Chronic Liver Disease Patients Patients with MRI and Morphometry
N 10 65 59
Gender (female/male) 3/7 31/34 29/30
Age (years), median (range) 33.5 (24–47) 56 (20–72)* 56 (20–72)*
BMI (kg/m2), mean 6 st. dev. 22.5561.77 29.0065.11# 28.9265.17#










*Significantly different from controls, p,0.05 Mann-Whitney test.
#Significantly different from controls, p,0.05 unpaired t-test. Abbreviations: AIH, autoimmune hepatitis; ALD, alcoholic liver disease; BMI, body mass index; HBV-HCV,
chronic viral hepatitis B/C; LIC, liver iron concentration; MRI, magnetic resonance imaging; NAFLD, non-alcoholic fatty liver disease – simple steatosis; NASH,
nonalcoholic steatohepatitis; NORM, normal; PSC, primary sclerosing cholangitis.
doi:10.1371/journal.pone.0059287.t001
Table 2. Analysis of the area under the receiver operating characteristic curve using the histopathologist’s visual estimate of fat in
the histological sections.
Cut-off MRI Cut off Value (a) AUC p value Sensitivity 95% CI Specificity 95% CI
$5% (Grade 0 vs 1–3)* .0.067 0.9615 ,0.0001 90.91 75.67 to 98.08 96.15 80.36 to 99.90
.33% (Grade 0–1 vs 2–3)* .0.135 0.9928 ,0.0001 100.0 85.18 to 100.0 97.22 85.47 to 99.93
.66% (Grade 0–2 vs 3)* .0.171 0.9724 ,0.0001 100.0 79.41 to 100.0 88.37 74.92 to 96.11
*Cut-offs are defined according to the NASH CRN grading system. Abbreviations: AUC, Area under receiver operating characteristic curve; CI, confidence interval; MRI,
magnetic resonance imaging.
doi:10.1371/journal.pone.0059287.t002
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The diagnostic performance of the MRI technique was largely
independent of the method of quantifying the fat content in biopsy
specimens, consistent with the strong coefficients of determination
between a, HIS-VIS, and HIS-MORPH. The AUCs based on
thresholds from the morphometric image analysis were similar to
those based on the visual cut-offs (Table 2, 3). To our knowledge,
no other study has used reference thresholds based on morpho-
metric image analysis to assess the diagnostic performance of in-
phase, opposed-phase MRI. The strong diagnostic performance of
the MRI method using two independent reference standards
suggests that it is robust. In our approach, the difference in T1
between fat and tissue water is exploited, by use of a high flip
angle, to distort the relationship between fat volume fraction and a
away from a linear 1:1 relationship to a non-linear relationship
(Figure 3). For tissues with a limited range of fat volume fraction, f,
(e.g. from 0.00 to 0.40) the sensitivity of the MRI measurement a
for predicting the fraction of protons in fat is potentially enhanced
for two reasons. Firstly, the differential of the relationship between
the MRI measurement a and the fraction of tissue protons in fat is
increased and secondly, the random error on a can be decreased
owing to better signal to noise ratios in the MRI data. The results
from our study therefore indicate that the particular adaptation of
the Dixon technique we used can be a useful non-invasive tool for
diagnosing liver fat across a range of liver diseases with high
sensitivity and specificity at all grades of steatosis.
This study also showed that the MRI a measurement was
strongly associated with visual (r2 = 0.83) and computer-assisted
morphometric (r2 = 0.84) estimates of liver fat from histological
specimens. In comparison, several studies have also reported
mostly strong correlations between MRI measurements and
estimates or grades of liver fat from histology specimens [10–
12,15,17–19,21–26,29,35,36]. These studies vary in the types and
numbers of patients and the MRI acquisition and processing used
(Table S3 in File S1), possibly explaining the large range in
reported coefficients of determination (0.26–0.89). Our MRI
versus biopsy results showed stronger coefficients of determination
than all but two of these studies [17,36]. However, our study was
larger and investigated a broader group of aetiologies compared to
these studies (Table S3 in File S1, [17,36]). The strong coefficients
of determination we observed between MRI and histological fat
measurements suggest that our data could form the basis of a
calibration between a quantitative MRI measurement sensitive to
liver fat content and histological estimates of fat.
The Bland Altman analysis summarized in Figure 5 gives an
indication of the precision of the MRI measurements for
Table 3. Analysis of the area under the receiver operating characteristic curve using the morphometric image analysis estimate of
fat in the histological sections.
Cut-off MRI Cut off Value (a) AUC p value Sensitivity 95% CI Specificity 95% CI
$0.014 .0.060 0.9639 ,0.0001 90.91 75.67 to 98.08 96.15 80.36 to 99.90
.0.043 .0.141 0.9925 ,0.0001 100.0 83.89 to 100.0 92.11 78.62 to 98.34
.0.077 .0.188 0.9869 ,0.0001 100.0 79.41 to 100.0 93.02 80.94 to 98.54
Abbreviations: AUC, Area under receiver operating characteristic curve; CI, confidence interval; MRI, magnetic resonance imaging.
doi:10.1371/journal.pone.0059287.t003
Figure 3. Plot of the MRI derived a value versus the fractional
area of fat vacuoles in the histological section (HIST-MORPH).
The solid line is a fit of Equation 3 to the data (r2 = 0.84).
doi:10.1371/journal.pone.0059287.g003
Figure 4. Plot of the MRI derived a value versus histopathol-
ogist’s estimate of percentage of hepatocytes containing a fat
vacuole (HIST-VIS). The solid line is the linear regression fit to the
data (r2 = 0.83).
doi:10.1371/journal.pone.0059287.g004
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measurement of liver fat insofar as the 95% limits of agreement are
a measure of the scatter of the data about the calibration curve.
Although some of the scatter will be attributable to sampling and
analytical errors in the biopsy measurement, these 95% limits of
agreement will enable comparison of the precision of other
techniques when compared against the biopsy method in the
future. While a separate prospective study with different scanners
and a different cohort of subjects will be required to validate the
accuracy of the technique for general use, there was no detectable
bias in the calibration between the three scanners used in this
study.
Our study has some limitations. Subjects did not have MRI and
liver biopsy performed on the same day with potential for changes
in hepatic steatosis levels between assessments. However, the
strong associations and diagnostic performance we observed
suggest that any changes in fat levels between biopsy and imaging
were not great. While our cohort size was larger than many
comparable studies, further validation studies on a larger
independent patient group would be desirable. In-phase, op-
posed-phase MRI methods can potentially give erroneous liver fat
estimates when the ratio of fat to water protons in the liver exceeds
0.5, leading to water/fat ambiguity issues [33]. In this study we
assumed that the number of water protons in the liver always
exceeded the number of fat protons. We made this assumption
based on the results of the Dallas Heart Study [37], which
reported that none of the 2287 subjects they studied with MRS
exceeded 50% hepatic triglyceride content. Compared with MRS
methods, whole liver imaging methods such as the one reported
here are unable to give detailed spectroscopic information on the
fat content of the liver.
In summary, we have shown that a rapid (single breath-hold),
routinely available, triple gradient echo MRI method has a high
degree of sensitivity and specificity to the amount of liver fat
measured in a biopsy specimen, either by a pathologist’s visual
estimate or by morphometric image analysis. Furthermore, this
study indicates that this MRI approach provides noninvasive
measurement of liver fat with high sensitivity and specificity for
diagnosing liver fat at all grades of steatosis in a cohort with a
range of liver conditions.
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Figure 5. Limits of agreement between liver fat fraction measurements. A) MRI HIST-MORPH fat fraction plotted against HIST-MORPH fat
fraction for the 59 subjects. The solid line is the line of equivalence. B) The difference between the natural logarithm of HIST-MORPH and the natural
logarithm of MRI HIST-MORPH plotted against the mean of the two logarithms for the 59 subjects. The solid lines indicate the 95% limits of
agreement and the dashed line is the mean difference between the logarithms of the two methods.
doi:10.1371/journal.pone.0059287.g005
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